Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2409-2416

  Mehta, Rajeshwari R ^a   McDermott, Jannette H ^a   Hieken, Tina J ^a   Marler, Kevin C ^a   Patel, Minu K ^a   Wild, Linda D ^a   Das Gupta, Tapas K ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PREDNISONE; VINCRISTINE;

AGE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; ONCOGENE C ERB; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 0031804617     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2409     Document Type: Article

References (32)

1. Schechter AL, Stern DF, Vaidyanathan L, et al: The neu oncogene: An erb-B related gene encoding a 185,000 Mr tumour antigen. Nature 312:513-516, 1984
2. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
3. Holmes WE, Sliwkowski MX, Akita RW, et al: Identification of heregulin, a specific activator of p185 erb-B2. Science 256:1205-1210, 1992
4. Lupu R, Colomer R, Kannan B, et al: Characterization of a growth factor that binds exclusively to the erb-B2 receptor and induces cellular responses. Proc Nat Acad Sci U S A 89:2287-2291, 1992
5. Peles E, Bacus SS, Koski RA, et al: Isolation of the neu/Her-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216, 1992
6. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235:177-182, 1987
7. Slamon DJ, Godophin W, Jones LA, et al: Studies of the Her-2 proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
8. Varley JM, Swallow JE, Brammar WJ, et al: Alterations to either c-erbB2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423-430, 1987
9. Thor AD, Schwartz LH, Koerner FC, et al: Analysis of c-erbB2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147-7152, 1989
10. Borg A, Baldetorp B, Ferno M, et al: erbB2 amplification in breast cancer with high rate proliferation. Oncogene 6:137-143, 1991
11. Van De Vijner MJ, Petersen JL, Mooi WJ, et al: Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Engl J Med 319:11239-11245, 1988
12. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of c-erbB2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
13. Allred DC, Clark GM, Tandon AK, et al: Her-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
14. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
15. Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene co-amplification units, hst-1/int-2 and c-erbB2/ear-1. Cancer Res 49:3104-3108, 1989
16. Muss H, Thor A, Barry A, et al: erbB2 expression and response to adjuvant chemotherapy in women with node-negative early breast cancer. N Engl J Med 330:1260-1266, 1994
17. Gusterson BA, Gelber RD, Goldhirsch A: Prognostic importance of c-erbB2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992
18. Klijn JG, Berns EM, Foekens JA: Prognostic factors and response to therapy in breast cancer. Cancer Surv 18:165-197, 1993
19. Berns M, Foekens JA, Van Staveren ILE, et al: Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-18, 1995
20. Battifors H, Gaffey M, Esteban J, et al: Immunohistochemical assay of neu/c-erbB2 oncogene product in early breast cancer: Retrospective follow-up study of 245 stage I and stage II cases. Mod Pathol 4:466-474, 1991
21. Haynes DF, Cirrincione C, Carney W: Elevated circulating Her-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer. Proc Amer Assoc Clin Oncol 12:58, 1993(abstr)
22. Andersen TI, Paus E, Nesland JM, et al: Detection of c-erbB2 related protein in sera from breast cancer patients. Acta Oncol 34:499-504, 1995
23. Fehm T, Maimonis P, Weitz S, et al: Influence of circulating c-erbB2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43:87-95, 1997
24. Yamauchi H, O'Neill A, Gelman R, et al: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the Her-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997
25. Volas GH, Leitzel K, Teramoto Y, et al: Serial serum c-erbB2 levels in patients with breast carcinoma. Cancer 78:267-272, 1996
26. Leitzel K, Teramoto Y, Konrad K, et al: Elevated c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
27. Cooper RBG, Holland JF, Glidewell O: Adjuvant chemotherapy of breast cancer. Cancer 44:793-798, 1979
28. Mehta RR, Beattie CW, Das Gupta TK: Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 20:125-132, 1991
29. Mehta RR, Graves JM, Shilkaitis A, et al: Breast carcinoma cell lines with metastatic potential in mice. Int J Oncol 6:731-736, 1995
30. Pegram MD, Finn RS, Arzoo K, et al: The effect of c-erbB2 Her-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
31. Benz CC, Scott GK, Sarup JC: Estrogen-dependent tamoxifen resistant tumorigenic growth of MCF-7 cells transfected with Her-2/ neu. Breast Cancer Res Treat 24:85-95, 1992
32. Rasbridge SA, Gillet CE, Seymour AM, et al: The effect of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70:335-341, 1994